DAWN earnings: a positive outcome, +6.9%

On August 4, 2022, Day One Biopharmaceuticals, Inc. reached its earnings. The result was a positive outcome, and the stock moved +6.9% in the window around the event. It had already run -14.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.